Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BioMerieux reports strong results for first nine months of 2017

BioMerieux reports strong results for first nine months of 2017

26th October 2017

BioMerieux has announced its financial results for the first nine months of 2017, reporting a cumulative sales total of 1.67 billion euros (1.48 billion pounds).

This represents a year-on-year increase of 10.7 percent at constant exchange rates and scope of consolidation, or 10.8 percent on a reported basis. This was driven by robust growth for the company's microbiology lines and sustained growth for its molecular biology portfolio.

These trends helped put the company on track to achieving its annual targets, with strong performers including the Biofire Filmarray line on an international basis, as well as the popular microbiology lines Vitek and Bact/Alert.

Key highlights of the most recent quarter include the signing of a new partnership agreement with Lumed and the launch of new antibiotic susceptibility tests under the Etest brand.

Alexandre Merieux, chief executive officer of BioMerieux, said: "Third-quarter growth for BioMerieux once again reflected the strong sales dynamic we have enjoyed for several quarters."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.